Advertisement

Thromboxane A2/Prostaglandin H2 Receptors: A Growing Family of Receptor Subtypes

  • Perry V. Halushka
  • Thomas A. Morinelli
  • Atsushi Masuda
  • Dale E. Mais
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)

Abstract

The presence of TXA2/PGH2 receptors on platelets, blood vessels and vascular smooth muscle has been established using both pharmacologic (1–2,5) and radioligand binding studies (3,6). However, debate exists as to whether or not platelet and vascular TXA2/PGH2 receptors are different. Pharmacological studies using human platelets and blood vessels from different species supported the notion that they were different (7, 8). However, since these studies crossed species and often used only a single compound, the possibility of species difference versus true receptor heterogeneity remained uncertain. Mais et al. (8–10) using analogues of 13-azapinane TXA2 provided pharmacological evidence that in the human and dog, the platelet and vascular TXA2/PGH2 receptors were different. Morinelli et al. (11) also provided pharmacological evidence that platelet and vascular receptors were different, using analogues of 10,10 difluoro TXA2. However, other pharmacologic and radioligand binding studies have failed to find differences between the platelet and vascular receptors even when crossing species (12–14). Thus, it remains controversial whether platelet and vascular TXA2/PGH2 receptors are different.

Keywords

Human Platelet Radioligand Binding Radioligand Binding Study Platelet Thromboxane Washed Human Platelet 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    G. C. LeBreton, D. L. Venton, S. E. Enke, and P. V. Halushka, 13-Azaprostanoic acid: A specific antagonist of the human blood platelets thromboxane endoperoxide receptor, Proc. Natl. acad. Sci. U.S.A. 76: 4097 (1979).CrossRefGoogle Scholar
  2. 2.
    P. V. Halushka, D. E. Mais, D. L. and Saussy, Jr., Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors, Ead Proc. 46: 149 (1987).Google Scholar
  3. 3.
    S. C. Hung, N. I. Ghali, D. L. Venton, and G. C. LeBreton, Specific binding of the thromboxane A2 antagonist 13azaprostanoic acid to human platelet membranes, Biochim. Riophys Actd. 728: 171 (1983).CrossRefGoogle Scholar
  4. 4.
    D. E. Mais, R. M. Burch, D. L. Saussy, Jr., P. J. Kochel, and P. V. Halushka, Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets, I. Pharmacol. Exp. Ther. 235: 729 (1985).Google Scholar
  5. 5.
    A. Hedberg, S. E. Hall, M. L. Ogletree, D. N. Harris, and E. C.-K Liu, Characterization of [5,6–3H]SQ29548 as a high affinity radioligand binding to thromboxane A2/prostaglandin H2 receptors in human platelets, sly Pharmacol. Exp. Ther. 245: 786 (1987).Google Scholar
  6. 6.
    P. M. Needleman, M. Minkes, and A. Raz, Thromboxanes: Selective biosynthesis and distinct biological properties, Science 193: 163 (1976).PubMedCrossRefGoogle Scholar
  7. 7.
    S. E. Burke, A. M. Lefer, K. C. Nicolaou, G. M. Smith, and J. B. Smith, Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues, Br. I. Pharmacol. 78: 287 (1983).CrossRefGoogle Scholar
  8. 8.
    D. E. Mais, D. L. Saussy, Jr., A. Chaikhouni, P. J. Kochel, D. R Knapp, N. Hamanaka, and P. V. Halushka, Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: Evidence for different receptors, I. Pharmacol. Exp. Ther. 233: 418 (1985).Google Scholar
  9. 9.
    D. E. Mais, C. Dunlap, N. Hamanaka, and P. V. Halushka, Further studies on the effect of epimers of thromboxane A2 antagonists on platelets and veins, Eur. J. Pharmacol. 111: 125 (1985).PubMedCrossRefGoogle Scholar
  10. 10.
    D. E. Mais, D. DeHoll, H. Sightler, and P. V. Halushka, Different pharmacologic activities for 13-azapinane thromboxane A2 analogs in platelets and blood vessels, EuxZ. 1. pharmacol. 148: 309 (1988).Google Scholar
  11. 11.
    T. A. Morinelli, A. K. Okwu, D. E. Mais, P. V. Halushka, V. John, C.-K. Chen, and J. Fried, Difluorothromboxane A2 and stereoisomers: Stable derivatives of thromboxane A2 with differential effects on platelets and blood vessels, Proc. Nat’l Acad Sci. U.S.A. 86: 5600 (1989).PubMedCrossRefGoogle Scholar
  12. 12.
    H. Akbar, A. Mukhopadhay, K. Anderson, E. Navran, K. Ramstedt, D. Miller, and D. Feller, Antagonist of prostaglandin-mediated responses in platelets and vascular smooth muscle by 13-azaprostanoic acid analogs, Biochem. Pharmacol. 34: 641 (1985).CrossRefGoogle Scholar
  13. 13.
    G. T. G. Swayne, J. Maguire, J. Dolan, P. Raval, G. Dane, M. Greener, and D. A. A. Owen, Evidence for homogeneity of thromboxane A2 receptors using structurally different antagonists, EuL. U. Pharmacol 152: 311 (1988).CrossRefGoogle Scholar
  14. 14.
    K. Hanasaki, K. Nakano, H. Kasai, H. and Arita, Biochemical characterizaton and comparison of rat thromboxane A2/prostaglandin H2 receptors in platelets and cultured aortic smooth muscle cells, Biochem. Pharmacol. 38: 2967 (1989).PubMedCrossRefGoogle Scholar
  15. 15.
    T. A. Morinelli, J. E. Oatis, Jr., A. K. Okwu, D. E. Mais, P. R. Mayeux, A. Masuda, D. R. Knapp, and P. V. Halushka, Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist, U Pharmacol. ExR. Ther. 251: 557 (1989).Google Scholar
  16. 16.
    A. Masuda, D. E. Mais, J. E. Oatis, Jr., and P. V. Halushka, Platelet and vascular thromboxane A2/prostaglanding H2 receptors: evidence for different subclasses in the rat. Biochemical pharmarol In press (1991).Google Scholar
  17. 17.
    R. Ross, The smooth muscle cell, V. Growth of smooth muscle in culture and formation of elastic fibers, I. Cell. Biol. 50: 172 (1971).CrossRefGoogle Scholar
  18. 18.
    A. Masuda, and P. V. Halushka, Thromboxane A2 receptors are influenced by cell density in cultured rat aortic smooth muscle cells, Life Sciences In press (1991).Google Scholar
  19. 19.
    D. E. Mais, C. Yoakim, Y. Guindon, J. Gillard, J. Rokach, and P. V. Halushka, Photoaffinity labelling of the human platelet thromboxane A2 prostaglandin H2 receptor, Biochim. Biophys. Acta 1012: 184 (1989).PubMedCrossRefGoogle Scholar
  20. 20.
    P. J. Munson, and D. Rodbard, LIGAND: A versatile computerized approach for characterization of ligand binding systems, Ate.. Biochem. 107: 220 (1980).CrossRefGoogle Scholar
  21. 21.
    P. M. Tymkewycz, R. L. Jones, N. H. Wilson, and C. G. Marr, Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements, Br. I. Pharmacol 102: 607 (1991).CrossRefGoogle Scholar
  22. 22.
    L. Furci, D. J. Fitzgerald, and G. A. FitzGerald, Heterogeneity of prostaglanding H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation, I. Pharm. Exp. Ther. In press (1991).Google Scholar
  23. 23.
    T. A. Morinelli, S. Niewiarowski, J. L. Daniel, and J. B. Smith, Receptor-mediated effects of a PGH2 analogue (U46619) on human platelets, A m .,I. physiol 253: H1035 (1987).Google Scholar
  24. 24.
    G. W. Dorn, Distinct platelet thromboxane A2/prostaglandin H2 receptor subtypes, SI. Clin. Invest. 84:1883 (1990).Google Scholar
  25. 25.
    P. R. Mayeux, T. A. Morinelli, T. C. Williams, E. S. Hazard, E. D. Mais, J. E. Oatis, D. A. Baron, and P. V. Halushka, Differential effect of pH on thromboxane A2/prostaglandin H2 receptor agonist and antagonist binding in human, I. Biol Chem In press (1991).Google Scholar
  26. 26.
    K. Takahara, R. Murray, G. A. FitzGerald, and D. J. Fitzgerald, The response to thromboxane A2 Analogues in human platelets, I. Biol. Chem. 265: 6836 (1990).Google Scholar
  27. 27.
    M. Hirata, Y. Hayashi, F. Ushikubi,Y. Yokota, R. Kageyama, S. Nakanishi, and S. Narumiya, Cloning and expression of cDNA for a human thromboxane A2 receptor, Nature 349: 617 (1991).PubMedCrossRefGoogle Scholar
  28. 28.
    N. Liel, D. E. Mais, and P. V. Halushka, Binding of a thromboxane A2/prostaglandin H2 agonist [3H]U46619 to washed human platelets, Prostaglandins 33: 789 (1987).PubMedGoogle Scholar
  29. 29.
    E. J. Kattelman, D. L. Venton, and G. C. Le Breton, Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548), Thromb. Res 41: 471 (1986).PubMedCrossRefGoogle Scholar
  30. 30.
    S. Narumiya, M. Okuma, and F. Ushikubi, Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species, Br. I. Pharmac. 88: 323 (1986).CrossRefGoogle Scholar
  31. 31.
    K. Hanasaki, T. Nagasaki, and H. Arita, Characterization of platelet thromboxane A2/prostaglandin H2 receptor by a novel thromboxane receptor antagonist, [3H]S-145, Biochem. Pharmacol. 38: 2007 (1989).Google Scholar
  32. 32.
    F. Ushikubi, M. Nakajima, M. Yamamoto, K. Ohtsu, Y. Kimura, M. Okuma, H. Uchino, M. Fujiwara, and S. Narumiya, [3H]S- 145 and [125I]I-S-145-OH: new radioligands for platelet thromboxane A2 receptor with low nonspecific binding and high binding affinity for various receptor preparations, Eicosanoids 2: 21 (1989).Google Scholar
  33. 33.
    D. E. Mais, P. J. Kochel, D. L. Saussy, Jr. and P. V. Halushka, Binding of an 1251-labelled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets, Molecular Pharmacol. 28: 163 (1985).Google Scholar
  34. 34.
    G. W. Dorn, II, Tissue-and species-specific differences in ligand binding to thromboxane A2 receptors, Am. I. physiol In press (1991).Google Scholar
  35. 35.
    G. W. Dorn II, and A. De Jesus, Binding of an [125I] labelled thromboxane A2/prostaglandin H2 receptor agonist to baboon platelets, Prostaglandins 38: 645 (1989).PubMedGoogle Scholar
  36. 36.
    K. Hanasaki, K. Nakano, H. Kasai, and H. Arita, Biochemical characterization and comparision of rat thromboxane A2/prostaglandin H2 receptors in platelets and cultured aortic smooth muscle cells, Biochem Pharmacol. 38: 2967 (1989).PubMedCrossRefGoogle Scholar
  37. 37.
    P. V. Halushka, D. E. Mais, and M. Garvin, Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to guinea-pig platelets, Eur. sl. Pharmacol. 131: 49 (1986).CrossRefGoogle Scholar
  38. 38.
    M. Nakajima, M. Yamamoto, F. Ushikubi, M. Okuma, M. Fujiwara, and S. Narumiya, Expression of thromboxane A2 receptor in cultured human erythroleukemia cells and its induction by 12–0-tetradecanoylphorbol-13-acetate, Biochem. Biophys. Bea Commun 158: 958 (1989).CrossRefGoogle Scholar
  39. 39.
    P. R. Mayeux, D. E. Mais, C. Carr, and P. V. Halushka, Human erythroleukemia cells express functional thromboxane A2/prostaglandin H2 receptors, 1. pharmacol Exp. Ther. 250: 923 (1989).Google Scholar
  40. 40.
    K. Hanasaki, K. Nakano, H. Kasai, H. Arita, K. Ohtani, and M. Doteuchi, Specific receptors for thromboxane A2 in cultured vascular smooth muscle cells of rat aorta, Biochem. Biophys. Res. Commun. 150: 1170 (1988).PubMedCrossRefGoogle Scholar
  41. 41.
    T. A. Morinelli, D. E. Mais, J. E. Oatis Jr., A. J. Crumbley III, and P. V. Halushka, Characterization of thromboxane A2/prostaglandin H2 receptors in human vascular smooth muscle cells, Life Sciences. 46: 1765 (1990).PubMedCrossRefGoogle Scholar
  42. 42.
    K. Hanasaki, K. Nakano, H. Kasai, H. Kurihara, H. and H. Arita, Identification of thromboxane A2 receptor in cultured vascular endothelial cells of rat aorta, Biochem Biophys. Res. Commun. 151: 1352 (1988).PubMedCrossRefGoogle Scholar
  43. 43.
    C. P. Sung, A. J. Arleth, and B. A. Berkowitz, Endothelial thromboxane receptors: biochemical characterization and functional implications, Biochem. Biophys. Res. Commun. 158: 326 (1989).PubMedCrossRefGoogle Scholar
  44. 44.
    D. L. Saussy Jr., D. E. Mais, G. P. Dube, D. E. Magee, K. A. Brune, W. L. Kurtz, and C. M. Williams, Characterization of a thromboxane A2/prostaglandin H2 receptor in guinea pig lung membranes using a radioiodinated thromboxane mimetic, Molecular Pharmacol. 39: 72 (1990).Google Scholar
  45. 45.
    B. M. Wilkes, J. Solomon, M. Maita, and P. F. Mento, Characterization of glomerular thromboxane receptor sites in the rat, Am. 1. Physiol. 256: F1111 (1989).Google Scholar
  46. 46.
    A. Hedberg, P. F. Mento, E. C.-K. Liu, A. M. Hollander, and B. M. Wilkes, Evidence for functional thromboxane A2-prostaglandin H2 receptors in human placenta, Am. 1. Physiol. 256: E256 (1989).Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Perry V. Halushka
    • 1
    • 2
  • Thomas A. Morinelli
    • 1
    • 2
  • Atsushi Masuda
    • 1
    • 2
  • Dale E. Mais
    • 1
    • 2
  1. 1.Medical University of South CarolinaCharlestonUSA
  2. 2.Eli Lilly Pharmaceutical CompanyIndianapolisUSA

Personalised recommendations